VR training startup, HTX Labs, recently brought on Houston-based Solvay GBU Peroxides North America as a client. Trainees can work on a digitized version of the plant that looks as real as could be. Courtesy of HTX Labs

Many employers are doing reality checks when it comes to workplace training. They're wondering how they can better train their workers. But they're realizing that traditional training can be dull and even unproductive, so they're enlivening and enriching their training through virtual reality.

Houston-based startup HTX Labs LLC is one of the tech companies at the forefront of the VR-infused modernization of workplace training. Among its customers are the United States Air Force, Mastercard, Rackspace, and Houston-based Solvay GBU Peroxides North America, a maker of hydrogen peroxide.

For the Air Force, HTX Labs creates software that provides immersive training for pilots on how to deal with emergency procedures in the air and on the ground. This is something that traditionally has been carried out only with expensive simulators. Mastercard and Rackspace rely on HTX Labs' technology to teach employees — through VR-generated replicas of actual workspaces — how to handle active-shooter situations, workplace violence, and fires.

Solvay turned to the company for VR-propelled help with training workers about loading and unloading hazardous materials and other aspects of maintaining safety around potentially dangerous chemicals. HTX Labs and Solvay will jointly resell their VR-based courses to other companies, says Scott Schneider, founder and CEO of HTX Labs.

At its core, the company's VR training zeroes in on the trainee, providing engaging, interactive experiences that stress "learning by doing," Schneider says.

Training programs that have been around for decades are "designed for trainers, not necessarily for trainees," he says.

"A PowerPoint presentation, a YouTube video — it's all about the message the trainer wants to convey as opposed to 'Let's think about how people actually learn.' Studies show people learn by actively doing — active learning versus passive learning," Schneider continues. "We married that idea of active learning with virtual reality and immersive technology to deliver a learning experience that increases retention and the development of muscle memory."

In a VR-based training session, participants are equipped with VR headsets and are plunged into realistic environments where they're presented with scenarios in which they, for instance, pick up a fire extinguisher and put out a blaze, or they land or eject from a military jet that's experiencing a problem such as an engine fire.

Schneider says this type of interactive training helps participants boost the amount of information they remember. According to the Society for Human Resource Management, VR learners retain 75 percent of what they've been taught, compared with a 10 percent retention rate from reading or listening to a presentation.

"It's a much better way, a much more realistic way to learn," Schneider says.

Employers big and small are catching on to this kind of advanced training. According to Schneider, software produced by companies like HTX Labs allows employers to conduct training that:

  • Avoids unsafe real-life settings in favor of safe virtual settings.
  • Does not disrupt workplaces.
  • Reduces costs.

A CNBC article says the cost-saving aspect appeals to a number of employers like Boeing, UPS, and Walmart.

"Training facilities cost hundreds of thousands, if not millions, of dollars to build. Sending out-of-town employees to them racks up travel expenses. And the lost time for training is considerable," the article reads.

By comparison, a one-time investment in VR hardware and software — technology that can be used by many workers — might cost a couple of thousand dollars per employee.

"Most companies in the private sector are dipping their toes into it a bit, maybe doing some stuff internally," Schneider says of VR-based training. "But on a larger scale, there's not a lot of players doing exactly what we're doing."

Schneider envisions HTX Labs, which was founded in 2017, expanding into training centered on augmented reality and mixed reality.

For the uninitiated, VR refers to computer-generated 3D environments that you interact with and are immersed in, according to Live Science. AR superimposes sounds, images and text onto what you see in the real world, along the lines of "Minority Report" or "Iron Man," Live Science explains.

"Mixed reality is the result of blending the physical world with the digital world," according to Microsoft. "Mixed reality is the next evolution in human, computer, and environment interaction, and unlocks possibilities that before now were restricted to our imaginations."

No matter the type of technology, HTX Labs strives to "humanize training" by putting the student at the center of the learning experience, Schneider says.

For now, HTX Labs produces VR training software under the EMPACT brand name and teams up with hardware vendors to sell turnkey offerings.

Today, the company employs 12 people, all of whom are in Houston. Schneider would like to increase HTX Labs' headcount by 50 percent before the end of 2019. Also this year, Schneider hopes to raise its first round of outside capital, but only after HTX Labs secures more private and government contracts. And he doesn't rule out enlarging the company through M&A activity.

Overall, Schneider sees tremendous potential for HTX Labs, as pretty much any employer can benefit from VR training for its workers. VR training — already part of a multibillion-dollar VR market — is expected to be so pervasive, in fact, that software review website Capterra predicts one-third of small and midsize businesses in the U.S. will be piloting VR training of employees by 2021.

"VR is … being used to enhance employee training to give workers immersive 'learning by doing' opportunities they can't find in a classroom or online course," Capterra notes. "It's a revolution in an area that's historically been static and unengaging for workers."


The U.S. Air Force also uses HTX Labs' technologies to train for emergency response procedures.Courtesy of HTX Labs

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Top stories: Houston's most-read health tech news of 2024

year in review

Editor's note: As the year comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. In the health tech category on InnovationMap, top stories included startup funding raised, IPO plans, FDA clearance, and more. Be sure to click through to read the full story.

New report ranks Houston top market for life sciences

Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. Photo by Natalie Harms/InnovationMap

Thanks in large part to producing hundreds of college-trained professionals, Houston’s life sciences industry ranks among the top U.S. markets for talent in 2024.

In a report published by commercial real estate services company CBRE, Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. From 2017 to 2022, Houston notched a growth rate of 32.4 percent in this category.

In 2022, the University of Houston led the higher education pack in the region, graduating 746 people with a bachelor’s degree or above in biological or biomedical sciences, according to the report. Continue reading.

Houston innovator raises pre-seed funding for health care staffing platform

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

A Houston health care innovator is celebrating an oversubscribed round of pre-seed funding to improve on her startup's unique staffing platform.

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. The new platform, which cuts out the middleman and lowers staffing costs, raised $700,000 in pre-seed funding that will go toward further development of the technology.

"Healthcare organizations spend $26 billion annually to support a crippling dependence on third-party agencies for connecting with clinical staff," Ademuyewo says in a news release. "Technological solutions that are pointed precisely to streamline and strengthen the relationships between highly specialized clinicians and their future employers are vital to alleviating this detrimental dependance, and central to our mission." Continue reading.

Houston regenerative medicine company to IPO, move toward more human trials

FibroBiologics will IPO this week. Photo via Getty Images

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.” Continue reading.

Houston organizations identify promising life science cos. at annual event

The Rice Alliance and BioHouston acknowledged innovations from a dozen promising health tech companies. Photo via Rice University

For the 13th year, the Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship celebrated innovative companies from around the world that are creating new treatments and solutions to today's biggest health care challenges.

This week, over 40 companies presenting their innovations across cancer, cardiovascular disease, biotechnology, and more. Nearly 700 venture capitalists, corporate innovation groups, angel networks, industry leaders, academics, service providers, and others attended the event on November 7 at Rice's BioScience Research Collaborative in the Texas Medical Center.

Just like in previous years, the event ended with the announcement of the 10 companies that were deemed "most promising" based on their pitches and technologies. Of the 10 companies named, six are headquartered in Houston and an additional two startups on the list have a presence here. Continue reading.

FDA greenlights Houston surgery robotics company's unique technology

EndoQuest Robotics secured an Investigational Device Exemption from the FDA for its clinical study. Photo via Getty Images

A Houston surgical robotics company has gotten a Investigational Device Exemption from the FDA to go forward with human trials.

This news allows EndoQuest Robotics to begin its Prospective Assessment of a Robotic-Assisted Device in Gastrointestinal Medicine (PARADIGM) study, which will be conducted at leading United States health care facilities, including Brigham and Women’s Hospital (Boston), Mayo Clinic (Scottsdale), Cleveland Clinic (Cleveland), AdventHealth (Orlando), and HCA Healthcare (Houston). The study will include surgeries on 50 subjects, who will hopefully begin to enroll in January.

“The foundational thesis is we're trying to make sure that the world's largest medical center is also the world's largest med tech innovation center,” Eduardo Fonseca, interim CEO of EndoQuest Robotics, tells InnovationMap. Continue reading.

Houston billionaire Tilman Fertitta nominated as ambassador to Italy

foreign affairs

Houston billionaire and Rockets owner Tilman Fertitta has been nominated to serve as the United States ambassador to Italy, according to U.S. President-elect Donald Trump.

On Saturday, Trump sent the following statement via Truth Social Post:

"I am pleased to announce that Tilman J. Fertitta has been nominated to serve as the United States Ambassador to Italy. Tilman is an accomplished businessman, who has founded and built one of our Country's premier entertainment and real estate companies, employing approximately 50,000 Americans. Tilman has a long history of giving back to the community through numerous philanthropic initiatives, which include children's charities, Law Enforcement, and the medical community. Additionally, Tilman is the longest serving Chairman of the Board of Regents for the University of Houston. He also owns the Houston Rockets Basketball Team. Congratulations to Tilman, and his remarkable family!"

Fertitta, 67, also is the chairman, CEO, and president of Landry's Inc. and the chairman of the University of Houston's board of regents.

"It is an honor to be nominated to serve my country as ambassador to Italy and I look forward to the process ahead. Italy is such an extraordinary country with its wonderful people, culture, and history and its strategic importance to The United States of America," Fertitta said.

---

Read the full story on CultureMap's news partner, ABC13.com.

Houston biotech biz to merge with public co., set local HQ

big deal

Houston-based Tvardi Therapeutics and Cara Therapeutics announced the companies have entered into a definitive merger agreement to combine in an all-stock transaction. Once completed, Houston will house the headquarters.

Tvardi is a clinical-stage biopharmaceutical company that focuses on the development of novel, oral, and small molecule therapies that target STAT3 to treat fibrosis-driven diseases. Tvardi will merge with a wholly owned subsidiary of Cara.

Once complete, the pre-merger Cara Therapeutics stockholders are expected to own approximately 17 percent of the combined company and pre-merger Tvardi Therapeutics investors are expected to own 83 percent of the combined company. Prior to adjustment from the issuance of the shares in the recently completed Tvardi financing and assuming Cara, which went public in 2014, has net cash at closing of between $22.9 million and $23.1 million with the percentage of the combined company that pre-merger Cara stockholders and pre-merger Tvardi stockholders will own upon the closing of the merger, which is subject to further adjustment if Cara’s net cash balance falls outside of the range.

“As we approach meaningful value inflection points next year, including two Phase 2 readouts of our lead program in idiopathic pulmonary fibrosis, followed by the readout in our hepatocellular carcinoma program, this merger, the recently completed financing, and becoming a publicly traded company give us access to the critical funding required to further advance our promising pipeline programs that address significant unmet needs,” Imran Alibhai, CEO of Tvardi Therapeutics, says in a news release.

Also, Tvardi has completed an approximately $28 million private financing from a syndicate of new and existing institutional investors. With the cash from both companies at closing and the proceeds of this financing, the post-merger company plans to have cash to fund its operating expenses and capital expenditure requirements into the second half of 2026.

“I am grateful to the Cara Board, leadership team, and shareholders who share our vision of Tvardi that is well-positioned to introduce effective, new treatment options to patients suffering from serious, chronic, fibrosis-driven diseases,” Alibhai continues.

In 2021, Tvardi emerged from stealth and closed a $74 million series B funding round led by New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.